BR112018000759A2 - método para fabricação de composto heterocíclico contendo nitrogênio e intermediário do mesmo - Google Patents

método para fabricação de composto heterocíclico contendo nitrogênio e intermediário do mesmo

Info

Publication number
BR112018000759A2
BR112018000759A2 BR112018000759-5A BR112018000759A BR112018000759A2 BR 112018000759 A2 BR112018000759 A2 BR 112018000759A2 BR 112018000759 A BR112018000759 A BR 112018000759A BR 112018000759 A2 BR112018000759 A2 BR 112018000759A2
Authority
BR
Brazil
Prior art keywords
containing heterocyclic
heterocyclic compound
nitrogen
manufacturing
illustrates
Prior art date
Application number
BR112018000759-5A
Other languages
English (en)
Japanese (ja)
Inventor
Nagato Yusuke
Mizumoto Shinsuke
Murakami Tatsuya
Tanaka Tomoyuki
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of BR112018000759A2 publication Critical patent/BR112018000759A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

um objetivo da presente invenção é proporcionar um método para fabricação industrial de um composto heterocíclico contendo nitrogênio que mostra uma excelente atividade inibidora de flt3, sendo útil como um ingrediente farmacêutico ativo de produtos farmacêuticos. a presente invenção proporciona um método de fabricação de um composto representado pela fórmula geral [14] ou um sal do mesmo, na fórmula, r1 ilustra um grupo alquila c1-6 que pode ser substituído e r8 ilustra um grupo abandonador ou semelhante.
BR112018000759-5A 2015-07-15 2016-07-14 método para fabricação de composto heterocíclico contendo nitrogênio e intermediário do mesmo BR112018000759A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015141034A JP6412471B2 (ja) 2015-07-15 2015-07-15 含窒素複素環化合物の製造方法およびその中間体
JP2015-141034 2015-07-15
PCT/JP2016/070758 WO2017010535A1 (ja) 2015-07-15 2016-07-14 含窒素複素環化合物の製造方法およびその中間体

Publications (1)

Publication Number Publication Date
BR112018000759A2 true BR112018000759A2 (pt) 2018-09-04

Family

ID=57758235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000759-5A BR112018000759A2 (pt) 2015-07-15 2016-07-14 método para fabricação de composto heterocíclico contendo nitrogênio e intermediário do mesmo

Country Status (21)

Country Link
US (2) US10435377B2 (pt)
EP (1) EP3323811B1 (pt)
JP (1) JP6412471B2 (pt)
KR (1) KR102032140B1 (pt)
CN (1) CN107848987B (pt)
AU (1) AU2016294197B2 (pt)
BR (1) BR112018000759A2 (pt)
CA (1) CA2992403C (pt)
DK (1) DK3323811T3 (pt)
ES (1) ES2729958T3 (pt)
HK (1) HK1245268A1 (pt)
IL (1) IL256809B (pt)
MX (1) MX2018000459A (pt)
NZ (1) NZ738953A (pt)
PL (1) PL3323811T3 (pt)
RU (1) RU2717830C2 (pt)
SG (1) SG11201800245QA (pt)
TR (1) TR201909774T4 (pt)
TW (1) TWI711605B (pt)
WO (1) WO2017010535A1 (pt)
ZA (1) ZA201800269B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202027749A (zh) 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
WO2020090969A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物の包装体
JPWO2020090968A1 (ja) * 2018-10-31 2021-09-16 富士フイルム株式会社 抗腫瘍剤を含む造粒物
TW202045174A (zh) 2019-02-28 2020-12-16 日商富士軟片股份有限公司 組合醫藥
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928839D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Novel compounds
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
CA2833852C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DK2001892T3 (da) 2006-03-17 2013-07-01 Ambit Biosciences Corp Imidazolthiazolforbindelser til behandling af proliferative sygdomme
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
DK2252597T3 (da) 2008-02-01 2014-04-28 Akinion Pharmaceuticals Ab Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
ES2645689T3 (es) 2008-05-21 2017-12-07 Ariad Pharmaceuticals, Inc. Derivados de fósforo como inhibidores de quinasas
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9169209B2 (en) 2011-05-04 2015-10-27 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
JP2013157540A (ja) 2012-01-31 2013-08-15 Toshiba Corp 半導体装置およびその製造方法
SG11201406674XA (en) * 2012-04-17 2014-11-27 Fujifilm Corp Nitrogen-containing heterocyclic compound or salt thereof
DK3059227T3 (da) * 2013-10-16 2019-08-26 Fujifilm Corp Salt af en nitrogen-holdig heterocyklisk forbindelse eller krystal deraf, farmaceutisk sammensætning og flt3-hæmmer
KR20150056683A (ko) 2013-11-15 2015-05-27 (주) 제일피앤티 대전 방지 필름 및 이를 이용한 쉴드 백
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof

Also Published As

Publication number Publication date
CA2992403A1 (en) 2017-01-19
PL3323811T3 (pl) 2019-09-30
IL256809B (en) 2019-06-30
EP3323811B1 (en) 2019-05-08
KR20180011848A (ko) 2018-02-02
US10562862B2 (en) 2020-02-18
JP2017019760A (ja) 2017-01-26
RU2018100967A (ru) 2019-08-16
AU2016294197A1 (en) 2018-01-25
CN107848987B (zh) 2020-10-23
TW201706254A (zh) 2017-02-16
US20180127382A1 (en) 2018-05-10
US10435377B2 (en) 2019-10-08
HK1245268A1 (zh) 2018-08-24
IL256809A (en) 2018-03-29
CA2992403C (en) 2019-12-31
US20190169133A1 (en) 2019-06-06
EP3323811A4 (en) 2018-05-23
EP3323811A1 (en) 2018-05-23
SG11201800245QA (en) 2018-02-27
MX2018000459A (es) 2018-09-07
WO2017010535A1 (ja) 2017-01-19
ZA201800269B (en) 2019-05-29
NZ738953A (en) 2019-06-28
AU2016294197B2 (en) 2018-07-26
TWI711605B (zh) 2020-12-01
CN107848987A (zh) 2018-03-27
RU2018100967A3 (pt) 2019-08-16
DK3323811T3 (da) 2019-07-22
TR201909774T4 (tr) 2019-07-22
JP6412471B2 (ja) 2018-10-24
ES2729958T3 (es) 2019-11-07
KR102032140B1 (ko) 2019-10-15
RU2717830C2 (ru) 2020-03-26

Similar Documents

Publication Publication Date Title
BR112018000759A2 (pt) método para fabricação de composto heterocíclico contendo nitrogênio e intermediário do mesmo
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
CO2018012171A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
PH12018500065A1 (en) Oxysterols and methods of use thereof
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
BR112017006809A2 (pt) compostos de ácido carboxílico úteis para inibir a prostaglandina e2 sintase-1 microssômica
MX2015013042A (es) Compuestos organicos.
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
DOP2016000253A (es) Nuevos compuestos
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112015029348A8 (pt) inibidores da bace, seus usos, e composição farmacêutica
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
CR20180111A (es) Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time